XyloCor Therapeutics, Inc. (XyloCor or the Company), a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular disease, today announced the appointment ...

Powering What's Next" event celebrates key milestones and the company's resilience as it enters its next chapter of innovation and ...

This year’s COP31 will play a crucial role in establishing a framework for the second Global Stocktake (GST2) in 2028, as well maintain momentum on climate action in a fracturing geopolitical ...